188 related articles for article (PubMed ID: 24162754)
21. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation.
Di Tommaso C; Valamanesh F; Miller F; Furrer P; Rodriguez-Aller M; Behar-Cohen F; Gurny R; Möller M
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2292-9. PubMed ID: 22427552
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts.
Lallemand F; Schmitt M; Bourges JL; Gurny R; Benita S; Garrigue JS
Eur J Pharm Biopharm; 2017 Aug; 117():14-28. PubMed ID: 28315447
[TBL] [Abstract][Full Text] [Related]
23. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
[TBL] [Abstract][Full Text] [Related]
24. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.
Weiss SL; Kramer WG
J Ocul Pharmacol Ther; 2019 Sep; 35(7):395-402. PubMed ID: 31355703
[No Abstract] [Full Text] [Related]
25. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels.
Kapoor Y; Chauhan A
Int J Pharm; 2008 Sep; 361(1-2):222-9. PubMed ID: 18577433
[TBL] [Abstract][Full Text] [Related]
26. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A.
Aliabadi HM; Mahmud A; Sharifabadi AD; Lavasanifar A
J Control Release; 2005 May; 104(2):301-11. PubMed ID: 15907581
[TBL] [Abstract][Full Text] [Related]
27. Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine.
Gebhardt BM; Kaufman HE
J Ocul Pharmacol Ther; 1995; 11(3):319-27. PubMed ID: 8590264
[TBL] [Abstract][Full Text] [Related]
28. Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability.
Onoue S; Suzuki H; Kojo Y; Matsunaga S; Sato H; Mizumoto T; Yuminoki K; Hashimoto N; Yamada S
Eur J Pharm Sci; 2014 Oct; 62():16-22. PubMed ID: 24836392
[TBL] [Abstract][Full Text] [Related]
29. Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.
Benítez del Castillo JM; Castillo A; Toledano N; Durán S; del Aguila C; Otero M; García-Sanchez J
Doc Ophthalmol; 1995; 91(1):49-55. PubMed ID: 8861636
[TBL] [Abstract][Full Text] [Related]
30. In vitro Characterization and Release Studies of Combined Nonionic Surfactant-Based Vesicles for the Prolonged Delivery of an Immunosuppressant Model Drug.
Rasul A; Imran Khan M; Ur Rehman M; Abbas G; Aslam N; Ahmad S; Abbas K; Akhtar Shah P; Iqbal M; Ahmed Al Subari AM; Shaheer T; Shah S
Int J Nanomedicine; 2020; 15():7937-7949. PubMed ID: 33116510
[TBL] [Abstract][Full Text] [Related]
31. Modern approaches to the ocular delivery of cyclosporine A.
Agarwal P; Rupenthal ID
Drug Discov Today; 2016 Jun; 21(6):977-88. PubMed ID: 27080149
[TBL] [Abstract][Full Text] [Related]
32. Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model.
Wolska E; Sznitowska M; Chorążewicz J; Szerkus O; Radwańska A; Markuszewski MJ; Kaliszan R; Raczyńska K
Eur J Pharm Sci; 2018 Aug; 121():95-105. PubMed ID: 29777856
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporin nanosphere formulation for ophthalmic administration.
Khan W; Aldouby YH; Avramoff A; Domb AJ
Int J Pharm; 2012 Nov; 437(1-2):275-6. PubMed ID: 22951866
[TBL] [Abstract][Full Text] [Related]
34. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems.
Sandri G; Bonferoni MC; Gökçe EH; Ferrari F; Rossi S; Patrini M; Caramella C
J Microencapsul; 2010; 27(8):735-46. PubMed ID: 21034366
[TBL] [Abstract][Full Text] [Related]
35. Supersaturated polymeric micelles for oral cyclosporine A delivery: The role of Soluplus-sodium dodecyl sulfate complex.
Xia D; Yu H; Tao J; Zeng J; Zhu Q; Zhu C; Gan Y
Colloids Surf B Biointerfaces; 2016 May; 141():301-310. PubMed ID: 26866892
[TBL] [Abstract][Full Text] [Related]
36. Self-micellizing solid dispersion of cyclosporine A for pulmonary delivery: Physicochemical, pharmacokinetic and safety assessments.
Suzuki H; Ueno K; Mizumoto T; Seto Y; Sato H; Onoue S
Eur J Pharm Sci; 2017 Jan; 96():107-114. PubMed ID: 27634579
[TBL] [Abstract][Full Text] [Related]
37. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.
Shen J; Deng Y; Jin X; Ping Q; Su Z; Li L
Int J Pharm; 2010 Dec; 402(1-2):248-53. PubMed ID: 20934499
[TBL] [Abstract][Full Text] [Related]
38. Molecular modeling of gel nanoparticles with cyclosporine A for oral drug delivery.
Tokarský J; Andrýsek T; Capková P
Int J Pharm; 2011 May; 410(1-2):196-205. PubMed ID: 21421033
[TBL] [Abstract][Full Text] [Related]
39. A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.
Guo H; Lee C; Shah M; Janga SR; Edman MC; Klinngam W; Hamm-Alvarez SF; MacKay JA
J Control Release; 2018 Dec; 292():183-195. PubMed ID: 30359668
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporine Amicellar delivery system for dry eyes.
Kang H; Cha KH; Cho W; Park J; Park HJ; Sun BK; Hyun SM; Hwang SJ
Int J Nanomedicine; 2016; 11():2921-33. PubMed ID: 27382280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
